Skip to main content

CORRECTION article

Front. Oncol., 08 April 2024
Sec. Thoracic Oncology
This article is part of the Research Topic Updates on Combination Therapy for Lung Cancer vol. II View all 6 articles

Corrigendum: Identification and validation of differentially expressed genes for targeted therapy in NSCLC using integrated bioinformatics analysis

  • 1Department of Pharmacy, Iqra University, Islamabad, Pakistan
  • 2Department of Pharmaceutics, Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan
  • 3Department of Medical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
  • 4Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China

In the published article, there was an error in affiliation of Meiqi Shi. Instead of “4Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China”, it should be “3Department of Medical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China”.

The authors apologize for this error and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: NSCLC, mutational analysis, differentially expressed genes, microarray, bioinformatics

Citation: Altaf R, Ilyas U, Ma A and Shi M (2024) Corrigendum: Identification and validation of differentially expressed genes for targeted therapy in NSCLC using integrated bioinformatics analysis. Front. Oncol. 14:1377858. doi: 10.3389/fonc.2024.1377858

Received: 28 January 2024; Accepted: 26 March 2024;
Published: 08 April 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Altaf, Ilyas, Ma and Shi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Meiqi Shi, shimeiqi1963@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.